GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Apollon Formularies PLC (AQSE:APOL) » Definitions » Ending Cash Position

Apollon Formularies (AQSE:APOL) Ending Cash Position : £0.05 Mil (As of Jun. 2023)


View and export this data going back to . Start your Free Trial

What is Apollon Formularies Ending Cash Position?

Apollon Formularies's Ending Cash Position for the quarter that ended in Jun. 2023 was £0.05 Mil.

Apollon Formularies's quarterly Ending Cash Position declined from Dec. 2021 (£0.31 Mil) to Jun. 2022 (£0.00 Mil) but then increased from Jun. 2022 (£0.00 Mil) to Jun. 2023 (£0.05 Mil).

Apollon Formularies's annual Ending Cash Position declined from Dec. 2019 (£0.10 Mil) to Dec. 2020 (£0.00 Mil) but then increased from Dec. 2020 (£0.00 Mil) to Dec. 2021 (£0.31 Mil).


Apollon Formularies Ending Cash Position Historical Data

The historical data trend for Apollon Formularies's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Apollon Formularies Ending Cash Position Chart

Apollon Formularies Annual Data
Trend Jun10 Jun11 Dec12 Dec13 Dec14 Dec17 Dec18 Dec19 Dec20 Dec21
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.44 0.10 0.10 - 0.31

Apollon Formularies Semi-Annual Data
Jun11 Jun12 Jun13 Dec13 Jun14 Dec14 Jun15 Dec17 Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Jun23
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 1.26 0.31 - 0.05

Apollon Formularies Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Apollon Formularies's Ending Cash Position for the fiscal year that ended in Dec. 2021 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=0.0029999999999999+0.302
=0.31

Apollon Formularies's Ending Cash Position for the quarter that ended in Jun. 2023 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=0.001+0.05
=0.05


Apollon Formularies Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Apollon Formularies's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.


Apollon Formularies (AQSE:APOL) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
6 Hope Street, Quayside House, Castletown, IMN, IM9 1AS
Apollon Formularies PLC is a London, England and Jamaican based medical cannabis pharmaceutical company specialising in research and treatment of patients with cancer and chronic pain. It is engaged in investing by seeking to acquire a direct and/or indirect interest in projects and assets in the agriculture and logistics sectors and the medicinal cannabis sector. The company focus on opportunities in Africa and Europe. It has created proprietary hybrid medical cannabis pharmaceutical strains, technology, formulations, and treatment products.

Apollon Formularies (AQSE:APOL) Headlines

From GuruFocus

FPA Capital Fund new buys in Q2 2015

By Tiziano Frateschi Tiziano Frateschi 07-14-2015

FPA Capital Fund Comments on For-Profit Education Stocks

By Holly LaFon Holly LaFon 12-09-2015

Weekly Guru Bargains Highlights: APOL, GNW, BTU, NIHD, OKE

By GuruFocus GuruFocus 06-30-2012

The Yacktman Focused Fund's Top Growth Stocks

By Dianne Tordillo Dianne Tordillo 01-25-2013

6 Highly Predictable Companies with Historically Low P/S Ratios

By Dianne Tordillo Dianne Tordillo 11-27-2012

Yacktman Funds Comments on Apollo Group

By Holly LaFon Holly LaFon 03-13-2013

FPA Capital Comments on Apollo

By Holly LaFon 07-29-2013

Sobering Findings About Student Debt

By OPM Insights Nelson Hsu 11-07-2015

Valuing Donald Yacktman's Portfolio: The Peter Lynch Fair Value

By Holly LaFon Holly LaFon 07-02-2012

Apollo Group: This Unloved Company Is Significantly Undervalued

By Matthew Dow Matthew Dow 05-09-2013